Conference of the International Clinical Hyperthermia Society 2012View this Special Issue
Conference Paper | Open Access
G. Andocs, N. Meggyeshazi, Y. Okamoto, L. Balogh, O. Szasz, "Bystander Effect of Oncothermia", Conference Papers in Science, vol. 2013, Article ID 953482, 6 pages, 2013. https://doi.org/10.1155/2013/953482
Bystander Effect of Oncothermia
Metastatic form of malignant tumor diseases is the most serious problem in oncology and the greatest challenge in tumor therapy. Conventional therapeutical approaches (surgery, irradiation, and chemotherapy) cannot manage this challenge in oncological practice. According to our theory, oncothermia treatment-induced immunogenic tumor cell death can be a very good basis for immunotherapy combination to make systemic tumor control from a local tumor destruction effect. We summarize the molecular basis of the oncothermia treatment-induced immunogenic cell death as a necessary basic condition to achieve the bystander effect.
Oncothermia (OTM) is an electrohyperthermia modality, a long-time (since 1989) applied method in oncology,  with great clinical success . OTM changes the paradigm of hyperthermia by targeted microscopic heat liberation at the membrane of the malignant cells. This method creates inhomogeneous heating, microscopic temperature differences far from thermal equilibrium. The tumor destruction efficacy and the role of temperature independent effects of the OTM were proven earlier by laboratory research and presented elsewhere [3, 4].
Bystander effect (abscopal effect) means that a local tumor treatment can affect the behavior of the far distant metastases. It was first discovered by radiooncologists and remained a higly controversial topic until recent years [5, 6]. Intensive research is conducting to reveal the immunbiological basis [7–9] and mechanism of action of this effect  and using the benefits in the regular oncological practice.
The objective is showing the newest results of oncothermia in research bystander effect.
2. Materials and Methods
2.1. Animal Model
HT29 human colorectal carcinoma cell line derived xenograft tumor model in nude mouse. See Figure 1.
2.2. Experimental Setup and Treatment
A single shot 30 min oncothermia treatment was done, reaching maximum 41-42°C intratumoral temperature, using the LabEHY system (Oncotherm Ltd.), under precise tumor temperature control using fluoroptic temperature measurement system (Lumasense, Luxtron m3300). See Figure 2.
2.3. Study Design
Time course study was performed. After a single shot treatment, sampling was made after 0, 1, 4, 8, 14, 24, 48, 72, 120, 168, and 216 hours. Three mice were sacrificed at each time point, keeping 5 sham-treated animals. See Figure 3.
2.4. Tumor Sample Processing
At the time of the sampling, the single-treatment animals were sacrificed and both the control and treated tumors were removed and studied in pairs. See Figure 4.
Due to the extremely high number of the tumor samples, tissue microarray (TMA) technology was used to perform accurate immunohistochemical reactions on many samples in one block. See Figure 5.
2.5. Immunohistochemistry (IHCH)
The following reactions and IHCH analysis were performed on the TMA samples: TUNEL (Invitrogen); TRAIL (DR5), HSP70 (Cell Signaling); Myeloperoxidase (Sigma); CD3 (Dako), CD4 (ABDSerotech).
2.6. Digital Microscopy Analysis
All histological slides were digitalized using Panoramic Slide Scanner (3DHisTech) and special software was used for imaging and evaluation. See Figure 6.
3.1. Histomorphological Changes
See Figure 7.
3.2. Appearance of the Hallmarks of Immunogenic Cancer Cell Death
3.2.1. Apoptotic Body Formation
See Figure 8.
3.2.2. TRAIL (DR5) Expression
See Figure 9.
3.2.3. HSP70 Expression Changes and Molecular Dynamics
See Figure 10.
3.3. Strong Local Immune Reaction
3.3.1. Myeloperoxidase (MPO) Detection
See Figure 11.
3.3.2. CD3 and CD4 Detection
See Figure 12.
(1)Oncothermia treatment can induce programmed cell death in the tumors which create many apoptotic bodies. Presence of apoptotic bodies in a destructed tumor tissue is essential to induce immunogenic reactions.(2)Oncothermia treatment-induced cell death is higly immunogenic, showing all the key molecular pattern dynamic changes what is characteristic of immunogenic tumor cell death.(3)Oncothermia treatment can induce strong and very unusual local immune reaction at the site of the treatment, long time after the electromagnetic intervention.(4)The local antitumor immune reaction might be systemic if the host has an intact immune system and proper immunstimulating agent is administered. This process can control the distant metastases by bystander effect, making possible the systemic control of the malignant disease with local treatment.
Ongoing intensive research is in progress on immunocompetent tumor models, to investigate and reveal the mechanism of action of this controlled bystander effect.
- A. Szasz, “Hyperthermia, a modality in the wings,” Journal of Cancer Research and Therapeutics, vol. 3, no. 1, pp. 56–66, 2007.
- A. Szasz, N. Szasz, and O. Szasz, Oncothermia: Principles and Practices, Springer, Heidelberg, Germany, 2010, http://www.springer.com/biomed/cancer/book/978-90-481-9497-1?changeHeader.
- G. Andocs, O. Szasz, and A. Szasz, “Oncothermia treatment of cancer: from the laboratory to clinic,” Electromagnetic Biology and Medicine, vol. 28, no. 2, pp. 148–165, 2009.
- G. Andocs, H. Renner, L. Balogh, L. Fonyad, C. Jakab, and A. Szasz, “Strong synergy of heat and modulated electromagnetic field in tumor cell killing,” Strahlentherapie und Onkologie, vol. 185, no. 2, pp. 120–126, 2009.
- S. C. Formenti and S. Demaria, “Systemic effects of local radiotherapy,” The Lancet Oncology, vol. 10, no. 7, pp. 718–726, 2009.
- W. F. Morgan and M. B. Sowa, “Non-targeted bystander effects induced by ionizing radiation,” Mutation Research, vol. 616, no. 1-2, pp. 159–164, 2007.
- R. P. A. Wallin, A. Lundqvist, S. H. Moré, A. von Bonin, R. Kiessling, and H. Ljunggren, “Heat-shock proteins as activators of the innate immune system,” Trends in Immunology, vol. 23, no. 3, pp. 130–135, 2002.
- S. R. Scheffer, H. Nave, F. Korangy et al., “Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo,” International Journal of Cancer, vol. 103, no. 2, pp. 205–211, 2003.
- O. Kepp, A. Tesniere, F. Schlemmer et al., “Immunogenic cell death modalities and their impact on cancer treatment,” Apoptosis, vol. 14, no. 4, pp. 364–375, 2009.
- A. D. Garg, D. Nowis, J. Golab, P. Vandenabeele, D. V. Krysko, and P. Agostinis, “Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation,” Biochimica et Biophysica Acta, vol. 1805, no. 1, pp. 53–71, 2010.
Copyright © 2013 G. Andocs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.